GoAI
Get started
Jupiter Neurosciences, Inc. logo

Jupiter Neurosciences, Inc.

JUNS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.20

+$1.03 · +19.92%

Aug 21, 4:00 PM ET

Pre-market

$5.2605

−$0.9395 · -15.15%

Aug 24, 6:39 AM ET

JUNS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

17

Strong Down

Sentiment

52

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Christer Rosen
Listed since
Dec 3, 2024
Employees
5

Market position

Day range

Current $6.20

52-week range

Current $6.20

Open
$8.23
Previous close
$5.17
Volume
52.41M
374.54× average
Average volume
139.92K
Average daily volume
Market cap
3M USD
Beta
1.96
Market reference 1
50-day average
$11.7344
-47.16% below average
200-day average
$41.1394
-84.93% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
36.85M USD
P/E (TTM)
-0.32×
P/B (TTM)
-9.45×
P/S (TTM)
46.45×
EV / EBITDA
-4.3×
Earnings yield
-24.48%
Free cash flow yield
-15.33%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
88.34%
Operating margin
-15166.68%
Net margin
-14220.12%
Return on equity
471.92%
Return on assets
-155.37%
Return on invested capital
-255.45%

Financial health

Debt / equity
-4.78×
Current ratio
0.65×
Altman Z-score
-23.07
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends4197%-12192%-28581%-44971%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2025: 80.59%Operating margin, FY2021: -612.36%Operating margin, FY2022: -1471.38%Operating margin, FY2025: -40873.19%Net margin, FY2021: -686.39%Net margin, FY2022: -2125.15%Net margin, FY2025: -39662.77%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2025 80.59%. Operating margin FY2021 -612.36%. Operating margin FY2022 -1471.38%. Operating margin FY2025 -40873.19%. Net margin FY2021 -686.39%. Net margin FY2022 -2125.15%. Net margin FY2025 -39662.77%.

Income trends

Revenue

21.8K USD-90.66%

Operating income

−8.91M USD-188.19%

Net income

−8.64M USD-254.35%
Income trends across reported periods1.59M USD−2.23M USD−6.04M USD−9.86M USDRevenue, FY2021: 638.04K USDRevenue, FY2022: 233.28K USDRevenue, FY2025: 21.8K USDOperating income, FY2021: −3.91M USDOperating income, FY2022: −3.43M USDOperating income, FY2023: −3.87M USDOperating income, FY2024: −3.09M USDOperating income, FY2025: −8.91M USDNet income, FY2021: −4.38M USDNet income, FY2022: −4.96M USDNet income, FY2023: −4.78M USDNet income, FY2024: −2.44M USDNet income, FY2025: −8.64M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 638.04K USD. Revenue FY2022 233.28K USD. Revenue FY2025 21.8K USD. Operating income FY2021 −3.91M USD. Operating income FY2022 −3.43M USD. Operating income FY2023 −3.87M USD. Operating income FY2024 −3.09M USD. Operating income FY2025 −8.91M USD. Net income FY2021 −4.38M USD. Net income FY2022 −4.96M USD. Net income FY2023 −4.78M USD. Net income FY2024 −2.44M USD. Net income FY2025 −8.64M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue21.8K USD——233.28K USD638.04K USD
Cost of goods sold4.23K USD————
Gross profit17.57K USD——233.28K USD638.04K USD
Research and development2.09M USD492.66K USD954.79K USD942.81K USD1.45M USD
Selling, general, and administrative6.84M USD2.6M USD2.92M USD2.72M USD3.1M USD
Operating expenses8.93M USD3.09M USD3.87M USD3.67M USD4.55M USD
Interest income—5.56K USD482 USD617 USD132 USD
Interest expense66.02K USD248.37K USD218.71K USD740.85K USD113.99K USD
Operating income−8.91M USD−3.09M USD−3.87M USD−3.43M USD−3.91M USD
Net income−8.64M USD−2.44M USD−4.78M USD−4.96M USD−4.38M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
14%
1 beat, 5 misses, 1 met estimate
Average EPS surprise
-37.63%
7 comparable reports
Latest EPS result
-5.06
Estimate -3.75 · Miss by 34.93%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-1.27-2.97-4.67-6.36Q1 '25MissQ2 '25MissQ3 '25MetQ4 '25BeatQ2 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 28, 2025: actual -3.76, estimate -1.5, surprise -150.67%, Miss. Q2 2025, reported May 15, 2025: actual -3.76, estimate -2.26, surprise -66.37%, Miss. Q3 2025, reported Aug 18, 2025: actual -5.26, estimate -5.26, surprise 0.00%, Met estimate. Q4 2025, reported Dec 22, 2025: actual -5.25, estimate -6, surprise +12.50%, Beat. Q2 2026, reported Apr 3, 2026: actual -5.61, estimate -5.25, surprise -6.86%, Miss. Q2 2026, reported May 21, 2026: actual -4.39, estimate -3.75, surprise -17.07%, Miss. Q3 2026, reported Aug 14, 2026: actual -5.06, estimate -3.75, surprise -34.93%, Miss. Q4 2026, reported Dec 2, 2026: actual —, estimate -3.75, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.7M1.8M910.07K15.85KQ3 '25EstimateQ4 '25EstimateQ2 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q3 2025, reported Aug 18, 2025: actual —, estimate 2.5M USD, surprise —, Comparison unavailable. Q4 2025, reported Dec 22, 2025: actual —, estimate 75K USD, surprise —, Comparison unavailable. Q2 2026, reported Apr 3, 2026: actual 21.8K USD, estimate 75K USD, surprise -70.94%, Miss. Q2 2026, reported May 21, 2026: actual 18.65K USD, estimate 225K USD, surprise -91.71%, Miss. Q3 2026, reported Aug 14, 2026: actual 24.25K USD, estimate 400K USD, surprise -93.94%, Miss. Q4 2026, reported Dec 2, 2026: actual —, estimate 602K USD, surprise —, Comparison unavailable.

JUNS news

https://thefly.com

Jupiter Neurosciences announces pricing of $2M registered direct offering

Jupiter Neurosciences announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross proceeds of the offering are…

Read source
globenewswire.com

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and…

Read source
benzinga.com

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) are surging Friday morning as related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S.…

Read source
globenewswire.com

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026

Read source
globenewswire.com

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson's disease program

Read source
globenewswire.com

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth

Read source

JUNS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding JUNS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
11.52K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research JUNS

research.disclaimer